
|Videos|September 17, 2018
Recurrent Metastatic ER+ Breast Cancer
Recurrent Metastatic ER+ Breast Cancer
Advertisement
A 52-Year-Old Woman with MetastaticER+ Breast Cancer
March 2015
- A 52-year-old postmenopausal woman was referred for multidisciplinary assessment after being diagnosed with breast cancer, found incidentally on routine screening mammogram
- Breast MRI revealed a 55-mm lesion in her left breast
- FH includes a great aunt on her mother’s side who died of breast cancer at age 50
- gBRCA1/2negative
- She underwent lumpectomy with axillary staging
- Biopsy findings:
- Histology: invasive ductal carcinoma, grade 3
- Hormone receptor status: ER+/ PR (-)
- HER2,IHC 1+
- OncotypeDx RS-high (27)
- Staging, T3BN0M0
- ECOG 1
- She completed 4 cycles of dose-dense doxorubicin/cyclophosphamide followed by 4 cycles of paclitaxel; she was then started on adjuvant letrozole
April 2017
- On routine follow-up, chest CT with contrast showed 4 small nodules in the left lung; biopsy confirmed metastatic breast cancer
- Letrozole was changed to fulvestrant; imaging at 3 months showed progressive disease
- She was subsequently started on treatment with capecitabine; imaging at 3 and 6 months showed a partial response
- She was scanned for pulmonary embolism
April 2018
- On routine follow-up:
- The patient complained of fatigue and new onset chest pain with deep breathing
- FDG PET/CT showed 2 new liver lesions and progression in the lung lesions
- ECOG 1
- The patient was started on eribulin IV, with a dosing schedule of days 1 and 8, every 21 days
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































